Prince Louis, 6, pens adorable message about his ‘granny and grandpa’ at Christmas carol service— and it will melt your heartIconic 90s R&B band speak out on first headline tour in 26 years and insist it’s not about ‘making money’Medtronic (NYSE:MDT) Stock Price Down 0% – Should You Sell?
Look, intellectually I'm a great believer in surprise and being challenged, not trying to optimize the fun out of everything. But when the rubber hits the road, I'm looking up guides to help me with games. In Indiana Jones and the Great Circle , though, there's an in-game hint system that is genuinely more streamlined and easy than trying to find something through Google. The Great Circle's hint system can be accessed through Indy's in-game camera, a tool you unlock early on in the Vatican open world zone. In addition to providing hints, the camera is used for some quest objectives, as well as for bagging extra experience points by snapping shots of interesting scenes throughout the world. For most of the game, I'm happy to report I was able to figure out Indy's brain teasers for myself. But there was one challenge late in the game where the hint system came in clutch. I just pointed the camera at the offending puzzle, snapped a shot, and a hint appeared in the upper left of the screen when looking through the camera. The hints are persistent too, remaining as a sort of log when looking through your camera until you solve the puzzle. They also escalate in specificity and direction as you keep taking pictures of the same puzzle. It starts out with gentle prodding, suggestions as to which environment objects are relevant to solving the puzzle and early steps to point you in the right direction. But if you're just really stuck (and maybe in a time crunch to hit a review embargo) you can just keep taking pictures until the game basically goes "Look, numb nuts, here's how to solve this thing. What, do you want me to hold your hand or something?" So if a puzzle in Indiana Jones and the Great Circle is giving you grief, I would recommend taking a picture of it instead of running to Google. It's genuinely quicker and more convenient, while not breaking your immersion in the game—something the devs expressed as their intention for the hint system in a pre-release interview with us. The biggest gaming news, reviews and hardware deals Keep up to date with the most important stories and the best deals, as picked by the PC Gamer team.Shares of Cullinan Therapeutics, Inc. ( NASDAQ:CGEM – Get Free Report ) traded down 2.9% on Thursday . The stock traded as low as $11.88 and last traded at $11.92. 28,103 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 640,126 shares. The stock had previously closed at $12.27. Analyst Ratings Changes A number of equities analysts have issued reports on CGEM shares. HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of Cullinan Therapeutics in a report on Wednesday, October 16th. UBS Group initiated coverage on shares of Cullinan Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Cullinan Therapeutics in a research report on Wednesday, September 18th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $31.67. Check Out Our Latest Analysis on CGEM Cullinan Therapeutics Stock Performance Cullinan Therapeutics ( NASDAQ:CGEM – Get Free Report ) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.09. As a group, sell-side analysts anticipate that Cullinan Therapeutics, Inc. will post -3.12 EPS for the current fiscal year. Insider Activity at Cullinan Therapeutics In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 3,489 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $12.52, for a total value of $43,682.28. Following the completion of the transaction, the insider now owns 104,453 shares of the company’s stock, valued at approximately $1,307,751.56. The trade was a 3.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, CEO Nadim Ahmed sold 8,400 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $11.87, for a total transaction of $99,708.00. Following the transaction, the chief executive officer now owns 263,150 shares in the company, valued at $3,123,590.50. This represents a 3.09 % decrease in their position. The disclosure for this sale can be found here . In the last three months, insiders have sold 24,582 shares of company stock valued at $322,057. 6.07% of the stock is owned by corporate insiders. Institutional Investors Weigh In On Cullinan Therapeutics A number of large investors have recently added to or reduced their stakes in CGEM. Bank of New York Mellon Corp boosted its stake in shares of Cullinan Therapeutics by 46.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 137,997 shares of the company’s stock worth $2,407,000 after buying an additional 43,757 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Cullinan Therapeutics by 73.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,883 shares of the company’s stock valued at $155,000 after acquiring an additional 3,758 shares during the period. Rhumbline Advisers boosted its position in Cullinan Therapeutics by 16.4% in the second quarter. Rhumbline Advisers now owns 54,351 shares of the company’s stock worth $948,000 after purchasing an additional 7,649 shares during the last quarter. Arizona State Retirement System bought a new stake in shares of Cullinan Therapeutics during the 2nd quarter valued at about $182,000. Finally, American Century Companies Inc. increased its position in shares of Cullinan Therapeutics by 32.9% during the 2nd quarter. American Century Companies Inc. now owns 76,018 shares of the company’s stock valued at $1,326,000 after purchasing an additional 18,840 shares during the last quarter. Institutional investors own 86.31% of the company’s stock. About Cullinan Therapeutics ( Get Free Report ) Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. See Also Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .MIAMI GARDENS, Fla. (AP) — Dolphins coach Mike McDaniel said he was caught off guard by reports early Tuesday that linebacker Shaq Barrett wants to unretire. The two-time Super Bowl winner signed a one-year deal with the Dolphins in March, then abruptly announced his retirement on social media in July, just days before the start of Miami's training camp. “Just to be candid, obviously there's a reason why you target and sign somebody," McDaniel said Tuesday afternoon. “I was fully caught off guard, or caught by surprise this morning as I found out.” McDaniel indicated the Dolphins have not had any conversations with Barrett recently. Miami holds the 32-year-old’s contractual rights. ESPN first reported the news. “It was kind of news as you guys got it,” McDaniel said. He also said he hasn't had a chance to think about Barrett potentially rejoining the team, and that his immediate focus is on Miami's Thursday night game at Green Bay. “The team is counting on me to think about the Packers,” he said. "I'll get with (GM) Chris (Grier), and we'll work through that. There's a ton of implications that go along with it in terms of team and roster stuff, so we'll work through that as we just got the news today.” Barrett has 400 tackles, 59 sacks, 22 forced fumbles and three interceptions in nine seasons — four with Denver and five with Tampa Bay. He was a second-team All-Pro with the Buccaneers in 2019, with a league-high 19 1/2 sacks. The Dolphins waived veteran safety Marcus Maye on Tuesday and activated rookie safety Patrick McMorris from injured reserve. Maye, who signed with the Dolphins in June, played in 11 games with three starts for Miami this season. He had 30 tackles and a tackle for loss. He could re-sign to the team's practice squad if he clears waivers. Maye previously played for New Orleans, but was cut in a money-saving move in March after two seasons with the Saints. Maye's release made room on the roster for McMorris, who was drafted in the sixth round by Miami in April. He began the season on injured reserve because of a calf injury. AP NFL: https://apnews.com/hub/nfl
The rapper Sean "Diddy" Combs and the suspected health care CEO assassin Luigi Mangione have decided on a similar defense strategy: Hire an Agnifilo. Or two. Marc Agnifilo is heading Combs' defense against racketeering conspiracy and sex trafficking charges , while Karen Friedman Agnifilo is leading Mangione's murder defense , with Marc in a support role. For much of the past few decades, the legal power couple often found themselves on opposite sides of such complex cases – she for the prosecution, and he for the defense. Now, they find themselves representing two of the most high-profile cases in the country today. From 2014 to 2021, Karen was the second-in-command in the Manhattan District Attorney's Office, which brought notable cases against defendants including Harvey Weinstein and Allen Weisselberg, the chief financial officer of the Trump Organization. She left the department in 2021 and has since moved into media, with a stint as a CNN legal analyst and contributor. Marc, meanwhile, has represented many of the targets of those DA investigations, including "pharma bro" Martin Shkreli, Nxivm founder Keith Raniere and former Goldman Sachs banker Roger Ng. He worked for the law firm Brafman & Associates from 2006 until earlier this year, when he split off to co-found the firm Agnifilo Intrater . Parents to three adult children, the law is what brought them together. The two met at the Manhattan DA's office in 1992 while working on a case in which two bagel store deliverymen got into an argument, and one cut off the other's arm with a machete, according to The New York Times . Their intersecting careers have at times led to legal conflicts of interest. In 2011, Karen had to recuse herself from the Manhattan DA's case against Dominique Strauss-Kahn when the former head of the International Monetary Fund hired the law firm where Marc worked. "It's never been awkward," Marc told The New York Times in 2011. "We're pretty regimented about it. If she's recused from a case, we really don't talk about it." The Agnifilos declined a CNN request for an interview. But that was then, and now, the Agnifilos have joined forces. Monday, when Mangione appeared in a New York courthouse for his arraignment, Karen was positioned to his left, and Marc sat on his right. Karen spoke to the court and criticized what she called the NYPD's over-the-top "perp walk" of her client, drawing on her years of service for perspective. "He was on display for everyone to see in the biggest staged perp walk I've ever seen in my career," she said. Karen Friedman Agnifilo has decades of experience in the legal field, primarily in the Manhattan DA's Office. She most recently served as the chief assistant district attorney under then-District Attorney Cyrus Vance Jr. until 2021. Her professional bio notes her "critical leadership role in prosecuting high-profile violent crime cases, including complex cases involving a mental health component." She managed a team of 1,500 people with a $120 million budget and "was also integral to creating the office's Human Trafficking Unit, Hate Crimes Unit, Antiquities Trafficking Unit, Terrorism Unit, its Cybercrimes and Identity Theft Bureau, as well as working on the creation of Manhattan's first Mental Health Court," according to her bio. She left public service in 2021 – complete with a bagpipe sendoff from the NYPD and DA's office – and moved to private practice. In an interview with the " Shut Up Mommy's Talking " podcast in 2022, Karen said moving into defense work was an adjustment. She cited her husband's experience in deciding whom to take on as a client. "My husband's also a criminal defense attorney and he's had some clients who just aren't nice to him. And I don't mean, like just not a little bit nice, I mean like abusive," she said. "And I don't want that at this stage in my life." "There's no crime necessarily that I wouldn't take or even set of factors that I wouldn't take," she added. "I do believe that everyone's entitled to a defense and to good representation, and I've always believed that." Karen said she has also been influenced by her children. Her twin daughters took an interest in politics and the Black Lives Matter movement during the COVID-19 pandemic, changing her thinking on the topic. "I have to credit them with opening my eyes to these issues," she said. Her third child has autism, she told the podcast, and she had frustrating experiences trying to get them help. She then used her experiences as a "special needs mom" to implement systems in the DA's office to help those with less money or opportunity, she said. "That became sort of my mission at the DA's office. It was very much into alternatives to incarceration, I pushed that very hard," she said. In recent years, Karen has moved into the media. She has served as the legal adviser to the long-running show "Law & Order," worked as a CNN legal analyst and opines on legal issues as the podcast host of "Legal AF" and "MissTrial" on the MeidasTouch Network. Her vocal media presence may offer a preview of her defense strategy. Earlier this month on CNN, before taking on Mangione as a client, she offered her thoughts on how the case could proceed. "It looks to me like there might be a not guilty by reason of insanity defense that they're going to be thinking about because the evidence is going to be so overwhelming that he did what he did," she said on December 10 . "As a former prosecutor in that office, I would be concerned that you have someone who is a valedictorian of his class, he was brilliant his whole life, he comes from this great family. I mean, something changed, significantly, something changed. And they're going to potentially have a not guilty by reason of insanity potential defense, so the prosecutors are going to try to shore that up as well in their investigation." Marc Agnifilo similarly began his career in prosecutors' offices and has since made a mark defending high-profile defendants in complex cases on the state, federal and international levels. A graduate of Connecticut College and Brooklyn Law School, he worked at the US Attorney's Office for the District of New Jersey and as a Manhattan assistant district attorney before turning to criminal defense, his website states . He has defended some of the most publicly reviled defendants of the past decade in Shkreli and Raniere, both of whom were convicted at trial. "You may find him repulsive, disgusting and offensive. We don't convict people in this country for being repulsive or offensive," he argued in Raniere's trial on charges of racketeering and sex trafficking. "Unpopular ideas aren't criminal. Disgusting ideas aren't criminal." In recent months, Marc took on Combs' case and has repeatedly asked the court to release the rapper on bond before trial. Other cases, many of which are listed on his website, have been resolved without charges or with short sentences. He told Law.com earlier this year his new law firm will focus on complex criminal litigation with an eye toward trying cases. "I have found that people come to me when they have something to say against the government's allegations," Marc said. "Very often that means they want to go to trial. So we all plan to do what we've always done: to try a bunch of cases. That's our supreme value."Aftermath Silver Ltd. ( OTCMKTS:AAGFF – Get Free Report ) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 853,000 shares, an increase of 30.6% from the November 30th total of 653,200 shares. Based on an average daily volume of 489,000 shares, the days-to-cover ratio is currently 1.7 days. Aftermath Silver Stock Performance Aftermath Silver stock opened at $0.29 on Friday. Aftermath Silver has a 52-week low of $0.12 and a 52-week high of $0.50. The stock’s 50 day moving average price is $0.35 and its two-hundred day moving average price is $0.30. About Aftermath Silver ( Get Free Report ) Read More Receive News & Ratings for Aftermath Silver Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aftermath Silver and related companies with MarketBeat.com's FREE daily email newsletter .A Comprehensive Guide to Gold Investment Companies
STILLWATER — Oklahoma State running back Ollie Gordon declared for the 2025 NFL Draft on Friday. “It’s been an amazing run,” Gordon posted on X. “From day one I knew I was in the right place. The love, support, and family I’ve gained here will always be a part of me. ... Now it’s time to take the next step in living out my dream. I’m excited to announce that I am officially declaring for the 2025 NFL Draft.” Although everyone around Stillwater and many elsewhere believed Gordon would declare for the draft following the season, a potential return wouldn’t have been the first time he defied conventional expectations. When Oklahoma State’s season began to go downhill this fall, national analysts suggested Gordon should sit out the rest of the season to protect his health and long-term goals and got picked up by others, including some OSU fans online. People are also reading... How did Oklahoma flip Cowboys QB commit less than 48 hours before signing day? Bill Haisten: As OSU regents meet, Mike Gundy’s contract should be a hot topic In a flash, OU loses a receiver to the portal and another from its 2025 recruiting class Ben Arbuckle is the new OU offensive coordinator. Have Sooners found the next Lincoln Riley? New abandoned shopping cart retrieval program draws criticism from outgoing city councilor Court 'bulldozes' tribal law in Tulsa case over jurisdiction, attorney says Meet Oklahoma's complete 2025 class. 5-star OT commits to Oklahoma Bill Haisten: Cooper Parker and the Bixby Spartans are at home in a new, $12M facility Stitt fires Cabinet secretary at odds with governor's stance on poultry lawsuit Berry Tramel: Extreme makeover needed for OSU football after thrashing by Colorado 10 potential candidates to replace Kasey Dunn as offensive coordinator at Oklahoma State A hairstylist’s assist, ‘divine intervention’ and $2.2 million for Inola High School Deep into Week 2, new names emerge in Tulsa football coaching search Berry Tramel: Jackson Arnold shows OU should save its high-end shopping for the portal Jenks football coach Keith Riggs resigns; DC Adam Gaylor named Trojans head coach “You know, my mom always taught me that you finish what you start,” Gordon said when asked why he stuck it out. “And who would I be to give up on my team, because our season not going how we wanted to go? ... They wasted their breath saying it because I’m not giving up on my team.” Even following what appeared to be a devastating injury at BYU that left Gordon unable to leave the field without assistance, the back returned and even converted a fourth-and-1 on a drive that gave Oklahoma State a lead in the final minutes. At times, it might have felt like Gordon’s efforts were futile, given how difficult it was for the Cowboys to run the ball, but he still finished with 880 rushing yards and averaged 4.6 yards per carry. He also scored 13 rushing touchdowns and one receiving. Where Gordon’s career ranks in the school record books: Sixth in rushing touchdowns (36) Tied for eighth in total touchdowns (39) 10th in rushing yards per game (90) 10th in yards per carry (5.56) Gordon is the second OSU player to declare he's leaving early for the pros. Linebacker Nick Martin made a similar decision earlier this week. “This program means a lot,” Gordon told reporters following his final home game. “Just from the coaches — you know, coach (Mike) Gundy taking me in and treating me like I’m his own son. He never treated us different from Gunnar or his other boy, Gage. But it's just the coaching staff, especially coach (John) Woz(niak). Coach Woz took me under his wing early, and that’s my dog. I feel like it’ll be weird without him. I love Coach Woz. He treats me like I’m his son, and I just love him.”Baroni: ‘Lazio should be proud with no regret’ over Atalanta drawDefensive tackle Nick Booker-Brown, who received All-Conference USA honorable mention in 2022, is headed to the Spartans. Click to share on Facebook (Opens in new window) Click to share on X (Opens in new window) Most Popular Chinese student’s drone got stuck in tree near Newport News Shipbuilding, leading to Espionage Act prosecution Chinese student’s drone got stuck in tree near Newport News Shipbuilding, leading to Espionage Act prosecution Longtime Phoebus Auction Gallery to close after New Year’s Day event Longtime Phoebus Auction Gallery to close after New Year’s Day event Juvenile humpback whale washes ashore on Outer Banks Juvenile humpback whale washes ashore on Outer Banks James City County officer, 17-year-old injured in Christmas Eve crash James City County officer, 17-year-old injured in Christmas Eve crash Williamsburg leaders to prioritize funding for regional Trail757 project Williamsburg leaders to prioritize funding for regional Trail757 project Journey of self: Williamsburg-area massage therapist helps others heal Journey of self: Williamsburg-area massage therapist helps others heal Purdue defensive back transfers to ODU Purdue defensive back transfers to ODU Fun to Do: Ice skating, holiday concerts, lights and more Fun to Do: Ice skating, holiday concerts, lights and more Partnership with Riverside Health seeks to improve wellness at area homeless shelters Partnership with Riverside Health seeks to improve wellness at area homeless shelters Get healthier in the new year with these resources in the Williamsburg area Get healthier in the new year with these resources in the Williamsburg area Trending Nationally Body found in wheel well of plane from Chicago to Maui How Diddy and Luigi Mangione spent Christmas in Brooklyn jail Massive invasive python is freed into the Palm Beach County wilderness. Here’s why ‘Baby Driver’ actor Hudson Meek dead at 16 Pregnant woman stabbed multiple times by pizza deliverer disgruntled about tip, sheriff says
What we know about Luigi Mangione, person of interest in UnitedHealthcare CEO's murder
IYOVIA: Empowering Growth Through A House of BrandsUS agency approves T-Mobile, SpaceX license to extend coverage to dead zones
None
( MENAFN - Robotics & automation News) Interview: Ambi Robotics founder sees 'huge opportunities' in new markets December 28, 2024 by David Edwards The founding of Ambi Robotics is somewhat obscured by the mist of history, but it started with some abandoned robots in a basement and the co-founders meeting at University of California Berkeley in 2018. Within about a year, the five founders made a breakthrough in simulation-to-reality transfer learning systems for robotics, calling it Sim2Real AI, which, in turn, led to the establishment of Ambidextrous Laboratories Inc, and a year later to the commercialization of the technology in the form of the AmbiSort parcel sorting system. The lightning quick pace of development led to huge interest from investors, who poured in $21 million into the startup by 2021, and another $32 million the following year. Now, three years on, Ambi Robotics can look back on numerous multimillion-dollar commercial installations and look forward to many more diverse deployments in the years ahead. In this interview, we speak to Jeff Mahler (main image), one of the founders of Ambi Robotics and its chief technology offer, and ask him about himself, his company and the future of robotics. Robotics & Automation News: Let's start by telling readers about yourself and your job at Ambi Robotics. Jeff Mahler : I'm Jeff Mahler, co-founder and chief technology officer of Ambi Robotics. I lead the engineering and product teams at Ambi, executing our technology strategy to develop highly dexterous AI-powered robotic systems that help people handle more in commercial logistics operations. I earned my Ph.D. from UC Berkeley, where my research focused on AI for robotic grasping. It was in Professor Ken Goldberg's AUTOlab where I met Stephen McKinley, David Gealy and Matt Matl, and we began combining our complementary skills to later become the co-founders of Ambi Robotics. My experiences in both industry and academia, including co-launching UC Berkeley's course on robotic manipulation and publishing award-nominated research on robotics and AI, have given me a strong foundation to develop advanced technologies and lead the creation of transformative robotic systems at Ambi Robotics. R&AN: And let's also introduce the company, Ambi Robotics, to readers. What are the main services and products and what is its position in the market. JM : Ambi Robotics is an AI and robotics company developing advanced solutions that scale ecommerce operations to meet demand while empowering humans to handle more. Our flagship solution, AmbiSort A-Series, uses robotic arms combined with advanced gantry technology to automate the sorting of mixed parcels into destination containers. It's modular and configurable, supporting customer demand for both bin-fed and conveyor-fed operations for high-efficiency parcel sorting. All of our robots run on our proprietary operating system, AmbiOS, which uses simulation-to-reality (Sim2Real) AI to train the robots 10,000 times faster in virtual simulations and then transfer those learnings to the real world, enabling the robots to handle any bag, box, envelope or unpackaged item with high speed and accuracy. With continuous learning capabilities, our technology's performance improves and evolves over time. Ambi Robotics is leading the way for AI-powered automation to solve operational challenges for shippers, positioning us at the forefront of innovation in the booming e-commerce shipping and logistics space. R&AN: What are the key problems that Ambi Robotics solves? When Ambi Robotics is asked to do a job, does it take over from human-centred systems or does it generally improve on a previously implemented technological system? Maybe give us a use case or two. JM : We're tackling some big challenges in ecommerce and supply chain, especially with the increasing demand for faster and more accurate parcel sorting. The AmbiSort A-Series system automates the sorting of mixed parcels from deep bins or automated conveyor induction into destination sacks, a traditionally manual and time-consuming process prone to errors, injuries and bottlenecks. By bringing in our AI-powered robotic systems, warehouses can boost throughput, accuracy and cut costs-all without needing to completely overhaul their existing process. Powered by Sim2Real AI, solutions from Ambi Robotics are ready to go from day one and add immediate value and cost savings. For example, during a partnership with a global shipping and mailing company, we deployed our AmbiSort products into their existing middle-mile operations to help automate and speed up parcel sortation. During our time together, we sorted 87 million packages and trained over 400 of their parcel handlers for higher-value, certified robot operator roles. With this move, their employees were able to focus on more complex and higher-value work while cutting operational costs. R&AN: What are the current challenges in parcel sortation? And how do you see the future playing out in terms of parcel sortation technologies? JM : Many warehouses run into problems with labor shortages combined with rising parcel volumes, especially around the peak holiday season, and inefficiencies in their traditional technology that may cause delays and errors. They also often struggle to scale operations to meet growing ecommerce demand while keeping costs manageable. For example, rising transportation costs are an ongoing challenge to meeting customer desires for lower shipping rates. Looking ahead, we see advanced robotics and automation taking on a larger role within warehouses, leveraging AI to create highly repeatable, efficient, scalable and flexible systems that can integrate with human workers and existing infrastructure to handle diverse parcel profiles efficiently. In addition, intelligent automation can create a fountain of data on every item handled in order to empower operations management to make smarter decisions on how to boost productivity. R&AN: At the moment, most of the end effectors on robots tend to be suction devices of some kind. Is there an alternative to this? Do you use any soft end effectors or human-like hands to deal with specific kinds of items? Is this diversification something that is relevant for you? JM : We primarily use suction-based end effectors because they are highly reliable and effective for handling a variety of parcel types, especially ones with non-porous, flat surfaces like cardboard. Our robots have multiple suction cups of different sizes and flexibility, so they can choose the best“fingertip” for whatever they're handling. While suction cups work great for a lot of items, we know there are objects, like irregularly shaped or delicate ones, that might need a different touch. To address this, we're looking into other types of end effectors, like parallel grippers, to extend the range of items our robots can handle. This flexibility is key as we keep improving our robots to handle an even wider range of objects efficiently and accurately. R&AN: What is the overall market potential for a company like yours? How big could it become, given the growth in e-commerce and so on, and considering the competition you are already up against? JM : The market potential is huge, especially with the massive growth in ecommerce. In 2022 there were over 150 billion packages shipped worldwide, and each one of those packages was touched by a human hand about 10 times. That means that there are over 1 trillion package“touches” occurring each year, and this number is growing rapidly. As more people shop online, the demand for fast, efficient and scalable fulfillment solutions is only going to keep rising. With robots like ours that can handle parcel sortation and even adapt to different types of packages, we're in a strong position to meet that demand. Our competitive edge is the ability to handle a wide variety of objects with precision and speed, thanks to our AI-driven system, and our ability to easily integrate with whatever warehouse layout is needed. As automation becomes a bigger part of the supply chain, we see a ton of room to grow and capture a significant share of the market. We're working alongside global leading logistics companies and continuing to evolve our technology to meet their needs as they grow. R&AN: While you currently specialise in parcel sortation, was that always what you had in mind? And could you diversify into new markets in the future. If so, which markets? JM : Ambi Robotics is all about real-world impact, and parcel sortation was where we saw the biggest opportunity to apply our technology due to the massive market opportunity. That being said, we've always had the vision to make our robots more versatile, and as we grow we can definitely see ourselves branching out into other markets. There are huge opportunities to provide robots that automate repetitive motions in other industries with high-volume material handling such as ecommerce order fulfillment, retail distribution, manufacturing and even recycling. MENAFN28122024005532012229ID1109037657 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.ExpressVPN Black Friday deal: Get up to 61 percent off a 30-month planOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 12, 2024-- Takeda ( TSE:4502/NYSE:TAK ) will host an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum of our Growth and Launch Products,” said Christophe Weber, Takeda chief executive officer. “The first three Phase 3 programs will read out in 2025, initiating a cadence of potential filings across multiple indications over the next several years.” Eight Regulatory Filings in FY2025 – FY2029 The late-stage pipeline includes oveporexton (TAK-861), zasocitinib (TAK-279), rusfertide (TAK-121), mezagitamab (TAK-079), fazirsiran (TAK-999) and elritercept (TAK-226). Combined these programs have potential peak revenue 1 of $10B - $20B. Data from three Phase 3 programs is expected to read out in 2025: oveporexton, a potential best-in-class and first-in-class investigational oral orexin receptor 2 agonist will report Phase 3 results in narcolepsy type 1; zasocitinib, an investigational next-generation, highly selective and potent oral allosteric tyrosine kinase 2 (TYK2) inhibitor will deliver Phase 3 results in psoriasis; and rusfertide, an investigational injectable hepcidin mimetic in development with partner Protagonist Therapeutics, will have Phase 3 results in polycythemia vera. Filings for these three indications are expected in fiscal years 2025 and 2026. Five additional indication filings for late-stage programs are on pace for fiscal years 2027 through 2029: zasocitinib in psoriatic arthritis; mezagitamab, an investigational anti-CD38 antibody providing rapid, selective and sustained depletion of disease-causing immune cells that could set a new standard for the treatment of immune thrombocytopenia (ITP) and immunoglobulin A neuropathy (IgAN); fazirsiran, an investigational RNA interference (RNAi) therapy that stops the production of misfolded abnormal protein Z-AAT directly addressing the pathology of alpha-1 antitrypsin deficiency liver disease (AATD-LD) and; elritercept, an investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS). Takeda recently signed an exclusive licensing agreement with Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. The agreement is subject to customary closing conditions, including completion of antitrust reviews. “Takeda has established an exciting, late-stage pipeline of transformative therapies that we believe will deliver value to our company and, most importantly, to the patients we serve around the world,” said Andy Plump, president of R&D at Takeda. “As we continue scaling our capabilities and maximizing R&D investment to deliver the late-stage pipeline, we are also progressing an exciting early-stage pipeline, supporting a cutting-edge research organization, and focusing on creative business development across our therapeutic areas to sustain Takeda’s future and continue to meet significant unmet patient needs.” 2024 R&D Day Agenda The meeting includes the following presentations and speakers: A Global, Innovation-Driven Biopharmaceutical Company Christophe Weber, President & CEO R&D Strategy and Pipeline Highlights Andy Plump, President, Research and Development Neuroscience: Deep-Dive on Orexin Franchise Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit and Head of Global Development Ramona Sequeira, President of Global Portfolio Division Gastrointestinal and Inflammation: Deep-Dive on Zasocitinib, Rusfertide, Mezagitamab, Fazirsiran Chinwe Ukomadu, Head of Gastrointestinal and Inflammation Therapeutic Area Unit Ramona Sequeira, President of Global Portfolio Division Oncology: Deep-Dive on Elritercept – Newly Announced Business Development Deal Teresa Bitetti, President Global Oncology Business Unit P.K. Morrow, Head of Oncology Therapeutic Area Unit Webcast Details A live webcast of the meeting begins at 8:30 a.m. JST December 13 (6:30 p.m. EST December 12). Presentations are available on the Investor Relations section of Takeda’s website where a video replay will be available following the meeting. About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com . Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. Peak Sales and PTRS Estimates References in this press release to peak revenue potential ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue potential ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. References in this press release to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda’s Portfolio Review Committee for use in internal planning. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Elritercept license agreement Elritercept is included for reference only. Takeda entered into an exclusive license agreement with Keros for global rights, in all territories outside of mainland China, Hong Kong and Macau, to Elritercept. The closing of the transaction is subject to receipt of regulatory approval(s), expected in the first calendar quarter of 2025. Takeda does not currently have rights to Elritercept. ___________________________ 1 References in this presentation to peak revenue potential are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. View source version on businesswire.com : https://www.businesswire.com/news/home/20241211148492/en/ CONTACT: Investor Relations Christopher O’Reilly Christopher.oreilly@takeda.com +81 (0) 90-6481-3412 Takeda Media Relations media_relations@takeda.com KEYWORD: MASSACHUSETTS UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: ONCOLOGY HEALTH NEUROLOGY CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Takeda Pharmaceutical Company Limited Copyright Business Wire 2024. PUB: 12/12/2024 05:30 PM/DISC: 12/12/2024 05:30 PM http://www.businesswire.com/news/home/20241211148492/en